Weight Management
Tirzepatide
Illustrative packaging. Actual dispensed packaging may differ.
Explore tirzepatide for weight management
Learn about tirzepatide and the questions to discuss during your online visit. Your provider determines whether treatment is appropriate based on your individual health needs.
Pricing will be published before online visits open.
A prescription is issued only if a licensed provider determines treatment is appropriate.
Review treatment-specific information with your provider.
Commonly reported effects may include nausea, vomiting, or diarrhea — most common, especially when starting or increasing dose and constipation or stomach pain.
View important safety informationWhat happens next
- 01
Share your history
Complete an online visit with your health history, medications, and goals.
- 02
Provider review
A licensed provider reviews your information and discusses appropriate next steps.
- 03
Ongoing guidance
If prescribed, follow your care plan. Patient services will be available when online visits open.
Common questions about Tirzepatide
How do I choose between tirzepatide and semaglutide?
Discuss both options with your provider. A treatment decision should consider your health history, current medications, potential risks, and other appropriate options—not only a comparison on a website.
Can I change my schedule myself?
Follow the schedule prescribed by your provider. Ask your care team before changing the dose or timing.
Does an online visit guarantee a prescription?
No. A licensed provider reviews your information and determines whether treatment is appropriate. A different option—or no prescription—may be recommended.
How do I use the medication if it is prescribed?
Follow the instructions supplied by your provider and dispensing pharmacy. Contact your care team if anything is unclear before using it. Do not use an illustrative website vial to determine a dose.
What will it cost?
Pricing will be published before online visits open.
How do I get help during treatment?
For general website or account questions, email support@surosrx.com. Patient services will be available when online visits open. Do not email sensitive medical details to general support.
Molecular profile
- Formula
- C₂₂₅H₃₄₈N₄₈O₆₈
- Molecular weight
- 4813.45 g/mol
- CAS number
- 2023788-19-2
- Sequence
- 39-amino-acid dual GIP/GLP-1 receptor agonist analog
Important Safety Information
Review the information below and discuss questions with your provider. This page does not replace your prescription instructions or individualized medical advice.
Compounded Tirzepatide is not FDA-approved. Its safety and effectiveness have not been established through large-scale human clinical trials of the compounded formulation, and product strength and quality may vary by compounding pharmacy. Use during pregnancy or breastfeeding, or in patients managing a serious or active medical condition, should be discussed with a provider first.
Reported effects (from available research and clinical reports — not an FDA-established safety profile):
- Nausea, vomiting, or diarrhea — most common, especially when starting or increasing dose
- Constipation or stomach pain
- Injection-site reactions
- Decreased appetite
Tirzepatide carries the same class boxed warning as other GIP/GLP-1 medications regarding thyroid C-cell tumors seen in animal studies; relevance to humans has not been determined. Discuss this with your provider.
Discuss with your provider before use if you have:
- A personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
- A history of pancreatitis
- Diabetic retinopathy
- Pregnancy or breastfeeding
Always use Tirzepatide exactly as prescribed, and discuss any questions or side effects with your healthcare provider.
